Retrospective 45 healthcare workes in Brazil, showing lower creation of antibodies with multiple doses of ivermectin, which may be expected due to the antiviral activity as demonstrated in multiple studies. Authors appear unaware of these studies, citing only earlier in vitro
research, which they misinterpret to suggest that therapeutic concentrations are not reached (for details on why this is incorrect see ). Authors combine no dose and one dose. Clinical outcomes and timing of treatment are not provided.
Pedroso et al., 8/12/2021, peer-reviewed, 11 authors.